Factor XIIIa cross-linking of the Marburg fibrin: formation of alpham.gamman-heteromultimers and the alpha-chain-linked albumin. gamma complex, and disturbed protofibril assembly resulting in acquisition of plasmin resistance relevant to thrombophila.
The truncated Aalpha-chain of fibrinogen Marburg is partly linked with albumin by a disulfide bond. Based on the recovery of the first six amino acid residues assigned to the subunit polypeptides of fibrinogen (the Aalpha-and gamma-chains) and albumin, 0.33 mol of albumin was estimated to be linked to 1 mol of the Marburg fibrinogen. When the Marburg fibrinogen was clotted with thrombin-factor XIIIa-Ca2+, various alpham gamman heteromultimers were produced, and part of the albumin was cross-linked to the gamma-chain. Acid-solubilized Marburg fibrin monomer failed to form large aggregates that could be detected by monitoring turbidity at A350, but it was able to enhance tissue-type plasminogen-activator-catalyzed plasmin generation, though not as avidly as the normal control, indicating that the double-stranded protofibrils had, to some extent, been constructed. This idea seems to be supported by normal factor XIIIa-catalyzed cross-linking of the fibrin gamma-chains. However, the cross-linked Marburg fibrin, being apparently fragile and translucent, was highly resistant against plasmin, and its subunit components were considerably retained for 48 hours as noted by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Although the exact mechanisms are still unclear, the albumin-incorporated factor XIIIa-cross-linked Marburg fibrin seems to have undergone a critical structural alteration(s) to acquire resistance against plasmin. This aquisition of plasmin resistance may be contributed to the postoperative pelvic vein thrombosis and recurrent pulmonary embolisms in the patient after caesarian section for her first delivery at the age of 20 years.
Sugo
T
T
Division of Hemostasis and Thrombosis Research, Institute of Hematology, Jichi Medical School, Tochigi, Japan.
Nakamikawa
C
C
Takebe
M
M
Kohno
I
I
Egbring
R
R
Matsuda
M
M
D003545:Cysteine / Q000737:chemistry; D004220:Disulfides / Q000737:chemistry; D004789:Enzyme Activation; D005176:Factor XIII / Q000737:chemistry*; D005337:Fibrin / Q000378:metabolism*; D015241:Fibrinogens, Abnormal / Q000378:metabolism*; D005341:Fibrinolysin / Q000378:metabolism; D006801:Humans; D046911:Macromolecular Substances; D011108:Polymers; D012709:Serum Albumin / Q000378:metabolism*; D013927:Thrombosis / Q000378:metabolism*; D010959:Tissue Plasminogen Activator / Q000378:metabolism; D000979:alpha-2-Antiplasmin / Q000378:metabolism
D004220:Disulfides; D015241:Fibrinogens, Abnormal; D046911:Macromolecular Substances; D011108:Polymers; D012709:Serum Albumin; D000979:alpha-2-Antiplasmin; C077397:fibrinogen Marburg; D005337:Fibrin; D005176:Factor XIII; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin; D003545:Cysteine